恆瑞醫藥(600276.SH):選舉孫飄揚為第八屆董事會董事長
格隆匯8月4日丨恆瑞醫藥(600276.SH)公佈,公司第八屆董事會第十次會議決議,審議通過《關於選舉第八屆董事會董事長的議案》 ,根據《公司法》《公司章程》等有關規定,現選舉孫飄揚為公司第八屆董事會董事長,任期至本屆董事會屆滿之日。根據《公司章程》有關規定,董事長為公司的法定代表人,因此公司法定代表人變更為孫飄揚。公司將按照有關規定完成法定代表人的工商登記變更手續。
審議通過《關於提名第八屆董事會董事候選人的議案》, 根據《公司法》《公司章程》等有關規定,公司董事會提名蔣素梅為公司第八屆董事會董事候選人,任期至本屆董事會屆滿之日。
蔣素梅,女,1963年生,1985畢業於中國藥科大學,1985年9月至今在江蘇恆瑞醫藥股份有限公司工作,曾任質檢部部長、質量總監、副總經理、常務副總經理、董事,現任公司副總經理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.